Literature DB >> 21611754

The variation of CD4+CD25+ regulatory T cells in the periphery blood and tumor microenvironment of non-small cell lung cancer patients and the downregulation effects induced by CpG ODN.

Yan-Ying Wang1, Xiao-Ye He, Ying-Yun Cai, Zhi-Jun Wang, Shao-Hua Lu.   

Abstract

The aim of the study was to observe the variation of CD4(+)CD25(+) regulatory T cells in periphery blood and tumor microenvironment of non-small cell lung cancer (NSCLC) patients and the effects of CpG ODN. The proportion of CD4(+)CD25(+) regulatory T cells, Foxp3 gene expression, levels of tumor growth factor-β (TGF-β) and immunoreactive fibronectin-γ (IFN-γ) in the periphery blood of 30 NSCLC patients and 30 healthy volunteers were compared. These indicators were compared before and after CpG ODN treatment. Foxp3 gene expression in the tumor microenvironment of NSCLC patients was also observed. The results showed CD4(+)CD25(+) regulatory T cell proportion, Foxp3 expression and TGF-β levels in the periphery blood of NSCLC patients were higher than those of healthy volunteers (p < 0.05), and these indicators of patients were significantly decreased after CpG ODN 2006 treatment (p < 0.05). Foxp3 expression in the metastatic lymph nodes was higher than that in the non-metastatic ones of NSCLC patients (p = 0.000). In conclusion, a rise in the proportion of CD4(+)CD25(+)Foxp3(+) regulatory T cells was demonstrated in the periphery blood and tumor microenvironments of NSCLC patients. CpG ODN 2006 downregulated the CD4(+)CD25(+)Foxp3(+) regulatory T cells proportion and TGF-β levels in the periphery blood of these patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21611754     DOI: 10.1007/s11523-011-0182-9

Source DB:  PubMed          Journal:  Target Oncol        ISSN: 1776-2596            Impact factor:   4.493


  19 in total

Review 1.  Immunosuppressive networks in the tumour environment and their therapeutic relevance.

Authors:  Weiping Zou
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

2.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.

Authors:  S Sakaguchi; N Sakaguchi; M Asano; M Itoh; M Toda
Journal:  J Immunol       Date:  1995-08-01       Impact factor: 5.422

3.  CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer.

Authors:  Mark J Smyth; Michele W L Teng; Jeremy Swann; Konstantinos Kyparissoudis; Dale I Godfrey; Yoshihiro Hayakawa
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

Review 4.  Immune suppression in the tumor microenvironment.

Authors:  Thomas F Gajewski; Yuru Meng; Helena Harlin
Journal:  J Immunother       Date:  2006 May-Jun       Impact factor: 4.456

5.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

6.  Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.

Authors:  Jörg Vollmer; Risini Weeratna; Paul Payette; Marion Jurk; Christian Schetter; Meike Laucht; Tanja Wader; Sibylle Tluk; Ming Liu; Heather L Davis; Arthur M Krieg
Journal:  Eur J Immunol       Date:  2004-01       Impact factor: 5.532

7.  CpG-Oligodeoxynucleotides activate tyrosinase-related protein 2-specific T lymphocytes but do not lead to a protective tumor-specific memory response.

Authors:  Lucia Sfondrini; Dario Besusso; Vincenzo Bronte; Beatrice Macino; Anna Rossini; Mario Paolo Colombo; Sylvie Ménard; Andrea Balsari
Journal:  Cancer Immunol Immunother       Date:  2004-03-18       Impact factor: 6.968

8.  Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation.

Authors:  S Read; V Malmström; F Powrie
Journal:  J Exp Med       Date:  2000-07-17       Impact factor: 14.307

9.  Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta.

Authors:  K Nakamura; A Kitani; W Strober
Journal:  J Exp Med       Date:  2001-09-03       Impact factor: 14.307

10.  Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors.

Authors:  Ping Yu; Youjin Lee; Wenhua Liu; Thomas Krausz; Anita Chong; Hans Schreiber; Yang-Xin Fu
Journal:  J Exp Med       Date:  2005-03-07       Impact factor: 14.307

View more
  10 in total

1.  Cryptotanshinone inhibits lung tumor growth by increasing CD4+ T cell cytotoxicity through activation of the JAK2/STAT4 pathway.

Authors:  Yonghong Man; Le Yang; Dongxian Zhang; Yongyi Bi
Journal:  Oncol Lett       Date:  2016-09-12       Impact factor: 2.967

Review 2.  Immunotherapy prospects in the treatment of lung cancer and mesothelioma.

Authors:  Joachim G Aerts; Lysanne A Lievense; Henk C Hoogsteden; Joost P Hegmans
Journal:  Transl Lung Cancer Res       Date:  2014-02

3.  Circulating autoantibody to CD25 may be a potential biomarker for early diagnosis of esophageal squamous cell carcinoma.

Authors:  S Guan; B Liu; C Zhang; K-H Lee; S Sun; J Wei
Journal:  Clin Transl Oncol       Date:  2013-02-20       Impact factor: 3.405

4.  A study of circulating anti-CD25 antibodies in non-small cell lung cancer.

Authors:  L Ye; X Li; S Sun; S Guan; M Wang; X Guan; K-H Lee; J Wei; B Liu
Journal:  Clin Transl Oncol       Date:  2012-12-21       Impact factor: 3.405

5.  Intraperitoneal prophylaxis with CpG oligodeoxynucleotides protects neutropenic mice against intracerebral Escherichia coli K1 infection.

Authors:  Sandra Ribes; Tanja Meister; Martina Ott; Sandra Redlich; Hana Janova; Uwe-Karsten Hanisch; Stefan Nessler; Roland Nau
Journal:  J Neuroinflammation       Date:  2014-01-23       Impact factor: 8.322

Review 6.  The Molecular Role of IL-35 in Non-Small Cell Lung Cancer.

Authors:  Yuqiu Hao; Hongna Dong; Wei Li; Xuejiao Lv; Bingqing Shi; Peng Gao
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

Review 7.  Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment.

Authors:  Marlies E Heuvers; Joachim G Aerts; Robin Cornelissen; Harry Groen; Henk C Hoogsteden; Joost P Hegmans
Journal:  BMC Cancer       Date:  2012-12-05       Impact factor: 4.430

8.  Effects of CpG Oligodeoxynucleotide 1826 on transforming growth factor-beta 1 and radiation-induced pulmonary fibrosis in mice.

Authors:  Xuan Li; Guoxiong Xu; Tiankui Qiao; Sujuan Yuan; Xibing Zhuang; Jihong Zhang; Hui Bin Sun
Journal:  J Inflamm (Lond)       Date:  2016-05-17       Impact factor: 4.981

9.  Further study of circulating IgG antibodies to CD25-derived peptide antigens in nonsmall cell lung cancer.

Authors:  Cairen Chen; Weili Wang; Qingyong Meng; Ning Wu; Jun Wei
Journal:  FEBS Open Bio       Date:  2016-02-16       Impact factor: 2.693

10.  Therapeutic Injection of a C-Type CpG ODN Induced an Antitumor Immune Response in C57/BL6 Mice of Orthotopically Transplanted Hepatocellular Carcinoma.

Authors:  Huijie Jia; Tiesuo Zhao; Di Zou; Xiaolong Jia; Ji Gao; Xiangfeng Song
Journal:  Oncol Res       Date:  2016       Impact factor: 5.574

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.